Jasper Therapeutics Reports Positive SPOTLIGHT Study Data

October 14, 2024

DENVER, Colo., Oct 14, 2024 (247marketnews.com)- Jasper Therapeutics (NASDAQ: JSPR) reported preliminary SPOTLIGHT data from its ongoing Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism, the two most prevalent sub types of CIndU.

14 of 15 participants (93%) enrolled in both dose cohorts of the study achieved a clinical response within the 6-week preliminary analysis period following administration, while 10 of 12 participants (83%) in the 120mg dose cohort experienced a complete response, with 1 participant experiencing a partial response.

Ronald Martell, Jasper’s President and CEO, commented, “We are very excited to report positive data from the SPOTLIGHT study, our first readout from a clinical trial evaluating briquilimab in chronic urticaria, with briquilimab driving rapid complete responses in over 80% of CIndU patients enrolled in the 120mg cohort.

“In addition to the responses observed, we are pleased that briquilimab was well tolerated in the study. These results demonstrate the ability of briquilimab to support optimal biologic dosing by rapidly delivering robust and durable clinical benefit along with a potentially differentiated safety profile. Additionally, we look forward to presenting initial data from all cohorts of the BEACON study in CSU in early January of next year. On behalf of the entire Jasper team, I’d like to thank both the investigators and the patients who participated in both studies, along with their families and caregivers.”

No serious adverse events and no grade 3 or higher adverse events were reported.

Martin Metz, M.D., Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin, added, “It is very exciting to see initial clinical data showing that treatment with briquilimab can lead to deep clinical benefit shortly after administration, particularly given the difficult-to-treat patient population in antihistamine refractory CIndU.

“I am also encouraged by the safety and tolerability profile observed in the SPOTLIGHT study thus far, particularly the lack of hypopigmentation or hair color changes. Patients with CIndU currently have very few treatment options, and I look forward to continuing to support the development of briquilimab in chronic urticarias.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (JSPR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.